按治疗(药物疗法、输血和骨髓移植)、最终用户(医院、专科诊所和其他最终用户)、地区和公司划分的全球镰状细胞病治疗市场——行业细分展望、市场评估、 2022-2032 年竞争情景、趋势和预测
- 发布日期: 2022年XNUMX月
- 报告编号: 44935
- 页数: 331
- 格式:
- keyboard_arrow_up
Sickle Cell Disease Treatment Market Overview:
The global market for Sickle-Cell Disease (SCD) Treatment was worth 美元1,903.2万 2021 年,预计将经历 17.9% 2023-2032 年的复合年增长率。
Sickle cell disease is a blood disorder that is inherited by hereditary, that causes rigid, abnormal, sickle-shaped blood cells (RBCs). It is caused by mutations within the beta-globin genes. The severity of the condition varies from person to person.
Global Sickle-Cell Disease Treatment Market Analysis
治疗分析
There are currently two options for sickle-cell disease treatment: palliative and symptomatic. SCD patients aged 16 and under can receive bone marrow donation. However, this is not a curative treatment. The risks of BMT in adults make it difficult for younger patients to have the procedure. Treatments include blood transfusions and medications to prevent or reduce complications.
Endari and Hydroxyurea remain the only approved drugs to treat SCD. A potential launch of promising candidates such as voxelotor (GBT 440), rivipansel, crizanlizumab, and Altemia will support the rapid growth of pharmacotherapy in sickle-cell disease treatment.
With a market share of over 48%, blood transfusion was the dominant treatment for sickle cell diseases. However, pharmacotherapy is expected to be the leader of the market by 2032 due to its strong pipeline and numerous promising drug launches during the forecast period.
最终用户分析
医院 segment will dominate the market during the forecast period. A volatile organic compound is a major reason for hospital admissions. It accounts for approximately 250, 000 emergency room visits per year in the US. This will favor the expansion and development of the hospital segment over the forecast period.
The growth of specialty clinics is being driven by the growing number of clinics. There are also frequent outpatient visits because SCD is often associated with multiple manifestations. This is another reason this segment has grown. The rising number of drug-using patients is driving the growth of care at home. This is likely to increase the growth in the other segments.
主要细分市场
通过治疗
- 药物治疗
- 输血
- 骨髓移植
由最终用户
- 医院
- 专科诊所
- 其他最终用户
市场动态
There are many types of sickle cell anemia. These can be genotypic or phenotypic depending on the mutations in hemoglobin genes. About 300,000 children are born each year with the disease. People of Middle Eastern, African, or South Asian descent often have sickle cell disease.
Global market growth is expected to be driven by improved healthcare, increased immigration, and a large population of African-Americans. The current treatment of chronic SCD primarily involves hydroxyurea injections and blood transfusions. A majority of patients are allergic to hydroxyurea. Patients with no resistance to hydroxyurea offer limited benefits and carry long-term safety risks.
Patients who have received blood transfusions can be exposed to blood-borne infections, iron overload, fever, and allergic reactions. Around 25% of patients suffering from sickle cell disease are transfusion-dependent. BMT is the only curative treatment.
However, it’s only recommended for a very small proportion of patients. Hydroxyurea was FDA-approved as a treatment for SCD until 2017. It was known under the names Droxia and Hydrea. Endari by Emmaus Life Sciences was approved by the FDA for the treatment of severe complications in SCD. It is available for both pediatric and adult patients. Endari was the FDA’s second approved drug.
The favorable government policies, increasing awareness of hematological cancers, increased investment, and improved healthcare infrastructure are expected to drive lucrative growth in emerging markets such as Nigeria and South Africa.
区域分析
North America held a dominant position in the global sickle cell anemia treatment market, with a 36% share in 2021. France is followed closely by the U.K. France is expected to see a CAGR of almost 18% but the U.S. will continue to hold its lead position throughout the forecast period. This could be due to factors like the possible launch of pipeline drugs and increased adoption of novel therapeutics.
The European migrant crises, which led to an increase of immigrant people from Africa, South Asia, and Western Asia, are major factors driving the market in EU5 markets. The seven main markets will expand at a cumulative CAGR of more than 17%.
报告中涵盖的主要地区和国家:
- 北美
- US
- 加拿大
- 墨西哥
- 欧洲
- 德国
- UK
- 法国
- 意大利
- 俄罗斯
- 西班牙
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 韩国
- 印度
- 其余亚太地区
- 南美
- 巴西
- 阿根廷
- 南美洲其他地区
- MEA
- GCC
- 南非
- 以色列
- 其余的MEA
市场份额和主要参与者分析:
Emmaus Medical, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer, Inc., Novartis AG, and Novartis AG are just a few of the players that operate in the sickle cells anemia market. Endari’s strong sales are expected to propel Emmaus Medical into the top spot in 2023. Global Blood Therapeutics Sancilio has the potential to capture a significant market share once their pipeline candidates-voxelotors or Altemia are approved.
The promising results of late-stage pipeline drugs, such as Novartis’ crizanlizumab from Novartis and Pfizer’s Rivipansel from Pfizer, have also been demonstrated. Market growth is expected to be positive with the introduction of disruptive therapeutics, such as Modus Therapeutics’ Sevuparin and Prolong Pharmaceuticals’ Sanguine. In the near future, gene therapies will be introduced to the sickle-cell disease treatment market, such as Bluebird Bio’s Lentiglobin, Bellicum Pharmaceuticals BPX 501, and Gamida Cells’ Cordin.
Маrkеt Кеу Рlауеrsѕ:
- Emmaus Medical Inc.
- 辉瑞公司
- Blood Therapeutics Inc.
- Bluebird bio Inc.
- 诺华公司。
- AstraZeneca Plc
- 礼来礼来
- 百特国际股份有限公司
- 其他关键人物
For the Sickle Cell Disease Treatment Market research study, the following years have been considered to estimate the market size:
属性 报告详情 历史年代
2016-2020
基础年
2021
预计年份
2022
短期预测年份
2028
预计年份
2023
长期预测年
2032
报告范围
竞争格局、收入分析、公司份额分析、制造商分析、制造商数量、关键细分市场、关键公司分析、市场趋势、分销渠道、市场动态、COVID-19 影响分析、现有参与者获取最大市场份额的策略,以及更多的。
区域范围
北美,欧洲,亚太地区,南美,中东和非洲
国家范围
美国、加拿大和墨西哥、德国、法国、英国、俄罗斯和意大利、中国、日本、韩国、印度和东南亚、巴西、阿根廷、哥伦比亚等沙特阿拉伯、阿联酋、埃及、尼日利亚和南非
常见问题
What is the size of the Sickle-Cell Disease Treatment market in 2021?The Sickle-Cell Disease Treatment market size is US$ 1,903.2 million in 2021.
What is the projected CAGR at which the Sickle-Cell Disease Treatment market is expected to grow at?The Sickle-Cell Disease Treatment market is expected to grow at a CAGR of 17.9% (2023-2032).
List the segments encompassed in this report on the Sickle-Cell Disease Treatment market?Market.US has segmented the Sickle-Cell Disease Treatment market by geographic (North America, Europe, APAC, South America, and Middle East and Africa). By Treatment, the market has been segmented into Pharmacotherapy, Blood Transfusion, and Bone Marrow Transplant. By End-User, the market has been further divided into Hospitals, Specialty Clinics, and Other End-Users.
List the key industry players of the Sickle-Cell Disease Treatment market?Emmaus Medical Inc., Pfizer Inc., Blood Therapeutics Inc., Bluebird bio Inc., Novartis AG., AstraZeneca Plc, Eli Lilly, Baxter International Inc., and Other Key Players are engaged in the Sickle-Cell Disease Treatment market
Which region is more appealing for vendors employed in the Sickle-Cell Disease Treatment market?North America is expected to account for the highest revenue share of 36%. Therefore, the Sickle-Cell Disease Treatment industry in North America is expected to garner significant business opportunities over the forecast period.
Name the key areas of business for Sickle-Cell Disease Treatment?The US, India, China, Canada, UK, Japan, & Germany are key areas of operation for the Sickle-Cell Disease Treatment Market.
Which segment accounts for the greatest market share in the Sickle-Cell Disease Treatment industry?With respect to the Sickle-Cell Disease Treatment industry, vendors can expect to leverage greater prospective business opportunities through the blood transfusion segment, as this area of interest accounts for the largest market share.
- 设置个人设置
我们的客户
单个用户
$5,999
$2,999
美元/每单位
保存50% |
多用户
$7,999
$3,499
美元/每单位
保存55% |
企业用户
$12,999
$4,499
美元/每单位
保存65% | |
---|---|---|---|
电子门禁 | |||
报告库访问 | |||
数据集 (Excel) | |||
打印 | |||
公司简介库访问 | |||
互动式仪表板 | |||
免费定制 | 没有 | 长达 10 小时的工作 | 长达 30 小时的工作 |
无障碍 | 1用户 | 2-5 用户 | 无限次 |
分析师支持 | 最长可达20小时 | 最长可达40小时 | 最长可达50小时 |
好处 | 下次购买最高可享受 20% 的折扣 | 下次购买最高可享受 25% 的折扣 | 下次购买最高可享受 30% 的折扣 |
立即购买(2,999 美元) | 立即购买(3,499 美元) | 立即购买(4,499 美元) |